Drug intelligence / Profile preview

Acegenix-P

Development stage
Unknown
Lead developer
Nilegenix
Modality
Small Molecules
Administration
Oral
01

Overview

Acegenix-P is a fixed-dose combination pharmaceutical product developed and marketed by Nilegenix, a generic pharmaceutical company based in India. It is composed of two active ingredients: aceclofenac, a non-steroidal anti-inflammatory drug (NSAID), and paracetamol (acetaminophen), an analgesic and antipyretic. Aceclofenac works by inhibiting the cyclooxygenase (COX) enzymes, thereby reducing the synthesis of prostaglandins that mediate pain and inflammation. Paracetamol provides additional pain relief and fever reduction, likely through central nervous system mechanisms. The drug is primarily indicated for the symptomatic relief of pain, inflammation, and fever associated with conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and general musculoskeletal pain.

Brand names
Acegenix-P
Other names
aceclofenac + paracetamol
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Acegenix-P.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acegenix-P.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call